Context Therapeutics Inc (CNTX)
$0.38
$-0.03
(-7.79%)
As on 28-Aug-2026 16:26EDT
Market cap
$35 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.6
-
Debt to Equity
0
-
Book Value
$0.4
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
91,879,177
8 Years Aggregate
CFO
$-100.18 Mln
EBITDA
$-54.70 Mln
Net Profit
$-108.81 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Context Therapeutics Inc (CNTX)
| -73.9 | -38.3 | -87.1 | -55.4 | -27.3 | -70.5 | -54.5 |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Context Therapeutics Inc (CNTX)
| 40.0 | -7.0 | 73.4 | -75.5 | -98.8 | -35.5 | 16,800.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Context Therapeutics Inc (CNTX)
|
0.4 | 35.3 | 0.0 | -46.0 | -- | -93.2 | -- | 1.0 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Context Therapeutics Inc (CNTX)
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect... T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Read more
-
Co-Founder, President, CEO & Director
Mr. Martin A. Lehr
-
Co-Founder, President, CEO & Director
Mr. Martin A. Lehr
-
Headquarters
Philadelphia, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Context Therapeutics Inc (CNTX)
What is the current share price of Context Therapeutics Inc (CNTX) Today?
The share price of Context Therapeutics Inc (CNTX) is $0.38 (NASDAQ) as of 28-Aug-2026 16:26 EDT. Context Therapeutics Inc (CNTX) has given a return of -27.33% in the last 3 years.
What is the current PB & PE ratio of Context Therapeutics Inc (CNTX)?
Since, TTM earnings of Context Therapeutics Inc (CNTX) is negative, P/E ratio is not available.
The P/B ratio of Context Therapeutics Inc (CNTX) is 1.02 times as on 28-Aug-2026, a 80 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.74 |
2.23 |
2024 |
-2.30 |
0.64 |
2023 |
-0.75 |
1.52 |
2022 |
-0.70 |
0.30 |
2021 |
-2.60 |
0.56 |
What is the 52 Week High and Low of Context Therapeutics Inc (CNTX)?
The 52-week high and low of Context Therapeutics Inc (CNTX) are Rs 3.62 and Rs 0.38 as of 31-Aug-2026.
What is the market cap of Context Therapeutics Inc (CNTX)?
Context Therapeutics Inc (CNTX) has a market capitalisation of $ 35 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Context Therapeutics Inc (CNTX)?
Before investing in Context Therapeutics Inc (CNTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.